Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MSC2156119J · 1 trial · 1 indication
DLT: defined using National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.0, as any of following toxicities: Grade 4 neutropenia for more than 7 days; greater than or equal to (\>=) Grade 3 febrile neutropenia; Grade 4 or Grade 3 thrombocytopenia with bleeding; \>=Grade 3 nausea despite adequate treatment; \>=Grade 3 any non-hematological AE (DLT defined specifically for following cases: \>=Grade 3 liver adverse event \[AE\] requiring recovery period of more than 7 days or to Grade 1 without liver metastases or Grade 2 with liver metastases ; \>=Grade 3 lipase and/or amylase elevation with confirmation of pancreatitis. An isolated lipase and/or amylase elevation of \>=Grade 3 without clinical/radiological evidence of pancreatitis was not classified as DLT); and \>=Grade 2 any AE not otherwise defined as DLT that, due to prolonged recovery to Grade 1 (or less) or baseline status, led to delay of treatment with IMP for more than 21 days.
| Arm | Type | Description |
|---|---|---|
| MSC2156119J | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MSC2156119J | DRUG | Subjects will be administered with MSC2156119J 215 mg, 300 mg and 500 mg orally once daily for repeated 21-day cycles until disease progression or unacceptable toxicity. |
Inclusion Criteria: * A subject with a histologically or cytologically confirmed diagnosis of malignant solid tumor which is refractory to standard therapy or to which no effective standard therapy is applicable * An archived tumor tissue is available or biopsy of tumor tissues can be newly perform...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
MSC2156119J is an investigational small molecule being studied for the treatment of solid tumors. It is currently in Phase 1 clinical development, and a completed trial in Japan evaluated its safety and tolerability in patients with solid tumors.
MSC2156119J is a c-Met inhibitor. It targets the c-Met receptor tyrosine kinase, which is involved in tumor growth and progression. By inhibiting c-Met, the drug aims to interfere with signaling pathways that promote cancer cell proliferation and survival.
MSC2156119J is being developed by Merck KGaA, a German multinational pharmaceutical company. The company's stock is traded under the ticker symbol MKGAF.
MSC2156119J is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial has been completed, and the drug remains under investigation for solid tumors.
MSC2156119J has one completed clinical trial, NCT01832506, titled 'A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors.' This trial enrolled 12 participants in Japan and was not randomized or blinded.